Interpace Biosciences Inc
OTC:IDXG
Interpace Biosciences Inc
Total Receivables
Interpace Biosciences Inc
Total Receivables Peer Comparison
Competitive Total Receivables Analysis
Latest Figures & CAGR of Competitors
Company | Total Receivables | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Interpace Biosciences Inc
OTC:IDXG
|
Total Receivables
$5m
|
CAGR 3-Years
-14%
|
CAGR 5-Years
-15%
|
CAGR 10-Years
-10%
|
|
DaVita Inc
NYSE:DVA
|
Total Receivables
$3B
|
CAGR 3-Years
5%
|
CAGR 5-Years
4%
|
CAGR 10-Years
5%
|
|
Quest Diagnostics Inc
NYSE:DGX
|
Total Receivables
$1.3B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
4%
|
CAGR 10-Years
3%
|
|
CVS Health Corp
NYSE:CVS
|
Total Receivables
$32.2B
|
CAGR 3-Years
11%
|
CAGR 5-Years
11%
|
CAGR 10-Years
13%
|
|
Cigna Corp
NYSE:CI
|
Total Receivables
$20.6B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Laboratory Corporation of America Holdings
NYSE:LH
|
Total Receivables
$2.2B
|
CAGR 3-Years
-9%
|
CAGR 5-Years
2%
|
CAGR 10-Years
10%
|
See Also
What is Interpace Biosciences Inc's Total Receivables?
Total Receivables
5m
USD
Based on the financial report for Mar 31, 2024, Interpace Biosciences Inc's Total Receivables amounts to 5m USD.
What is Interpace Biosciences Inc's Total Receivables growth rate?
Total Receivables CAGR 10Y
-10%
Over the last year, the Total Receivables growth was 7%. The average annual Total Receivables growth rates for Interpace Biosciences Inc have been -14% over the past three years , -15% over the past five years , and -10% over the past ten years .